#### Application No. Applicant(s) Habermann et al. 10/076,632 **Notice to Comply** Examiner Art Unit Paper No 1656 Steadman, D. 200601011

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: A sequence listing with those sequences recited in claims 32-33.
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or <b>substitute</b> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the <b>specification</b> .
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



## SYNNESTVEDT & LECHNER LLP

2600 ARAMARK TOWER

IIOI MARKET STREET

PHILADELPHIA, PA 19107-2950

TELEPHONE (215) 923-4466

FACSIMILE (215) 923-2189
E-MAIL synnlech@synnlech.com
www.synnlech.com
December 22, 2006

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of P. Habermann Application No. 10/076,632 Filed February 19, 2002

Art Unit 1652 Examiner D. Steadman Confirmation No. 2603

Nucleic Acids Encoding Hirudin Fusion Proteins and Methods for Producing Hirudin Fusion Proteins

(Atty. Docket No. P 30,612 USA)

### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Friday, December 22, 2006.

Gene J. Yao

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### STATEMENT OF SUBSTANCE OF INTERVIEW

Sir:

On October 11, 2006, the undersigned conducted an interview by telephone with the Examiner. The Examiner's February 17, 2006 Action and applicant's June 15, 2006 Reply thereto were discussed. Prior to the interview, the Examiner had reviewed the Reply.

The Examiner advised that, in view of the amendment to independent Claim 1 submitted in the Reply, it appears that his Section 102 rejection of independent Claim 1 and Claims 7 to 14, 21, and 25 to 28, which are dependent therefrom, has been overcome. The Examiner advised, however, he will conduct a review to determine if there is any additional art which may be relevant to the claims.

The Examiner advised further that he has not been able to fully review applicant's arguments with respect to the Section 112 rejections and that he would require additional time for further consideration thereof.

In addition, the Examiner advised that a revised Sequence Listing must be submitted to include the amino acid sequence recited in Claims 32 and 33 and that he would issue a Notice to Comply.

Respectfully submitted,

Gene J. Yao, Esquire

Reg. No. 47,193

Attorney for Applicants

Synnestvedt & Lechner LLP 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107-2950

Tele: (215) 923-4466

Fax: (215) 923-2189

**GJY** 

S:\S\SANOFI-AVENTIS\Patents\P30612 USA\PTO\Interview Summary.doc